Pamela M Murnane1, Renee Heffron, Allan Ronald, Elizabeth A Bukusi, Deborah Donnell, Nelly R Mugo, Edwin Were, Andrew Mujugira, James Kiarie, Connie Celum, Jared M Baeten. 1. aDepartment of Epidemiology bDepartment of Global Health, University of Washington, Seattle, Washington, USA cUniversity of Manitoba, Department of Internal Medicine, Winnipeg, Canada dCenter for Microbiology Research, Kenya Medical Research Institute eDepartment of Obstetrics & Gynaecology, University of Nairobi fDepartment of Obstetrics & Gynaecology, Kenyatta National Hospital, Nairobi gDepartment of Reproductive Health, Moi University, Eldoret, Kenya hDepartment of Medicine, University of Washington iStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Abstract
BACKGROUND: For women at risk of HIV-1, effective contraception and effective HIV-1 prevention are global priorities. METHODOLOGY: In a clinical trial of pre-exposure prophylaxis (PrEP) for HIV-1 prevention in HIV-1-serodiscordant couples, we estimated the effectiveness of hormonal contraceptives (oral contraceptive pills, injectable depot medroxyprogesterone acetate, and hormonal implants) for pregnancy prevention relative to no contraception among 1785 HIV-1-uninfected women followed up to 36 months. We compared the effectiveness of each method among women assigned PrEP versus placebo. Contraception was not required for participation, but was offered on-site and was recorded monthly; incident pregnancy was determined by monthly urine testing. RESULTS: For women using no contraception, overall pregnancy incidence was 15.4% per year. Women reporting oral contraceptive use had comparable pregnancy incidence to women using no contraception, and this lack of contraceptive effectiveness was similar for those assigned PrEP and placebo (17.7 and 10.0% incidence per year, respectively; P-value for difference in effect by PrEP use = 0.24). Women reporting injectable contraception had reduced pregnancy incidence compared to those reporting no contraception, which did not differ by arm (PrEP 5.1%, placebo 5.3% per year; P-value for difference = 0.47). Contraceptive effectiveness was highest among women using implants (pregnancy incidence <1% per year in both arms). CONCLUSION:PrEP had no adverse impact on hormonal contraceptive effectiveness for pregnancy prevention. As seen previously in similar populations, women reporting contraceptive pill use had little protection from pregnancy, possibly due to poor adherence. Injectable or implantable hormonal contraception and PrEP provide effective prevention for pregnancy and HIV-1.
RCT Entities:
BACKGROUND: For women at risk of HIV-1, effective contraception and effective HIV-1 prevention are global priorities. METHODOLOGY: In a clinical trial of pre-exposure prophylaxis (PrEP) for HIV-1 prevention in HIV-1-serodiscordant couples, we estimated the effectiveness of hormonal contraceptives (oral contraceptive pills, injectable depot medroxyprogesterone acetate, and hormonal implants) for pregnancy prevention relative to no contraception among 1785 HIV-1-uninfectedwomen followed up to 36 months. We compared the effectiveness of each method among women assigned PrEP versus placebo. Contraception was not required for participation, but was offered on-site and was recorded monthly; incident pregnancy was determined by monthly urine testing. RESULTS: For women using no contraception, overall pregnancy incidence was 15.4% per year. Women reporting oral contraceptive use had comparable pregnancy incidence to women using no contraception, and this lack of contraceptive effectiveness was similar for those assigned PrEP and placebo (17.7 and 10.0% incidence per year, respectively; P-value for difference in effect by PrEP use = 0.24). Women reporting injectable contraception had reduced pregnancy incidence compared to those reporting no contraception, which did not differ by arm (PrEP 5.1%, placebo 5.3% per year; P-value for difference = 0.47). Contraceptive effectiveness was highest among women using implants (pregnancy incidence <1% per year in both arms). CONCLUSION: PrEP had no adverse impact on hormonal contraceptive effectiveness for pregnancy prevention. As seen previously in similar populations, women reporting contraceptive pill use had little protection from pregnancy, possibly due to poor adherence. Injectable or implantable hormonal contraception and PrEP provide effective prevention for pregnancy and HIV-1.
Authors: Kenneth Ngure; Renee Heffron; Nelly R Mugo; Connie Celum; Craig R Cohen; Josephine Odoyo; Helen Rees; James N Kiarie; Edwin Were; Jared M Baeten Journal: AIDS Date: 2012-02-20 Impact factor: 4.177
Authors: Renee Heffron; Deborah Donnell; Helen Rees; Connie Celum; Nelly Mugo; Edwin Were; Guy de Bruyn; Edith Nakku-Joloba; Kenneth Ngure; James Kiarie; Robert W Coombs; Jared M Baeten Journal: Lancet Infect Dis Date: 2011-10-03 Impact factor: 25.071
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: James M Smith; Rachna Rastogi; Ryan S Teller; Priya Srinivasan; Pedro M M Mesquita; Umadevi Nagaraja; Janet M McNicholl; R Michael Hendry; Chuong T Dinh; Amy Martin; Betsy C Herold; Patrick F Kiser Journal: Proc Natl Acad Sci U S A Date: 2013-09-16 Impact factor: 11.205
Authors: Deborah J Donnell; Jared M Baeten; Ting Hong; Jairam R Lingappa; Andrew Mujugira; Edith Nakku-Joloba; David Bangsberg; Connie Celum Journal: AIDS Behav Date: 2013-02
Authors: Renee Heffron; Nelly Mugo; Edwin Were; James Kiarie; Elizabeth A Bukusi; Andrew Mujugira; Lisa M Frenkel; Deborah Donnell; Allan Ronald; Connie Celum; Jared M Baeten Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Kerry A Thomson; Jared M Baeten; Nelly R Mugo; Linda-Gail Bekker; Connie L Celum; Renee Heffron Journal: Curr Opin HIV AIDS Date: 2016-01 Impact factor: 4.283
Authors: Sarah K Calabrese; Rachel W Galvao; John F Dovidio; Tiara C Willie; Cara B Safon; Clair Kaplan; Abigail Caldwell; Oni Blackstock; Nicole J Phillips; Trace S Kershaw Journal: AIDS Patient Care STDS Date: 2020-03 Impact factor: 5.078